Charles Todd Eary

USPTO Granted Patents = 17 (Patent Applications = 3)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 4.6

ph-index = 4

Forward Citations = 82(Granted Patents)

Location History:

Boulder, CO (US) (2011)
Stamford, CT (US) (2020 - 2023)
Longmont, CO (US) (2007 - 2024)

Company Filing History:

Luitpold Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12268666 - Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide (2025-04-08),

2. 12138250 - Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2024-11-12),

3. 12109193 - Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide (2024-10-08),

4. 12102621 - Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2024-10-01),

5. 11963950 - Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2024-04-23),

6. 11807651 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2023-11-07),

7. 11214571 - Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof (2022-01-04),

8. 11098064 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile (2021-08-24),

9. 11091486 - Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof (2021-08-17),

10. 10786489 - Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile (2020-09-29),

11. 10745419 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2020-08-18),

12. 8404681 - Xanthones, thioxanthones and acridinones as DNA-PK inhibitors (2013-03-26),

13. 8304407 - 8-substituted benzoazepines as toll-like receptor modulators (2012-11-06),

14. 8242115 - Materials and methods to potentiate cancer treatment (2012-08-14),

15. 8044083 - Kinase inhibitors and methods of use thereof (2011-10-25),

Title: The Innovations of Inventor Charles Todd Eary from Longmont, CO

Introduction: Charles Todd Eary, a talented inventor based in Longmont, CO, has made significant contributions in the field of pharmaceuticals with a total of 13 patents to his name.

Latest Patents: Among his notable inventions is the formulation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile. This patent focuses on the use of the compound for treating various diseases, including cancers and gastrointestinal disorders.

Career Highlights: Charles Todd Eary has been associated with leading companies in the pharmaceutical industry, including Array Biopharma Inc. and Loxo Oncology, Inc. His innovative work has significantly impacted the development of new treatment options for a range of medical conditions.

Collaborations: Throughout his career, Charles has collaborated with esteemed professionals in the field, such as Stacey Spencer and Laurence Edward Burgess. These collaborations have strengthened the impact of his inventions and patents in the pharmaceutical sector.

Conclusion: Charles Todd Eary's dedication to innovation and his remarkable contributions to the pharmaceutical industry highlight his position as a key figure in the field of medical research. His patents stand as a testament to his commitment to advancing treatment options for a range of diseases and disorders.

This text is generated by artificial intelligence and may not be accurate.